The clinical effects of vasopressin receptor antagonists in heart failure.

Mihai Gheorghiade*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The neurohormone arginine vasopressin (AVP) is a promising target in the treatment of heart failure because AVP promotes congestion and hyponatremia, each of which is associated with poor outcomes. Diuretics are standard therapy for heart failure, but they have several limitations, including worsening renal function and hyponatremia. Blocking AVP leads to effective aquaresis, improvements in hemodynamics and renal function parameters, weight loss, and normalization of serum sodium, without changes in blood pressure or heart rate. In placebo-controlled trials in the inpatient and outpatient setting, the AVP receptor antagonist tolvaptan reduced body weight and edema and normalized serum sodium in patients with heart failure.

Original languageEnglish (US)
JournalCleveland Clinic journal of medicine.
Volume73 Suppl 2
StatePublished - Jun 1 2006

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The clinical effects of vasopressin receptor antagonists in heart failure.'. Together they form a unique fingerprint.

Cite this